NCT06414889View on ClinicalTrials.gov

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

PHASE1RecruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
RUNX1 Familial Platelet Disorder
Interventions
DRUG

G-CSF (filgrastim or biosimilar)

Given by IV or SC

PROCEDURE

Apheresis

Given by procedure

DRUG

Plerixafor

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

RUNX1 Foundation

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER